Annals of Neurology · 1986 · 47 citations · 23 references
MedicineNeurologyPharmacotherapyClinical NeuroscienceNeuropathologyNeuropharmacologyAxonal DegenerationDemyelinating DiseasesDemyelinating DisordersNeurologic PathophysiologyPeripheral Nerve DisordersPeripheral NeuropathiesElectrophysiological FindingsElectrophysiological StudyMyelination ImpairmentPeripheral Nerve DemyelinationPeripheral Neuropathy PathophysiologyPeripheral Neuropathy PharmacotherapyPhenytoin TherapySural Nerve Biopsy
Phenytoin has been implicated as a causative agent in peripheral neuropathy, although structural changes in nerve have not been characterized. A 47-year-old man was seen with clinical and electrophysiological signs of peripheral neuropathy after 30 years of phenytoin administration. Despite a modest dose of phenytoin (300 mg/day) blood levels were 31 to 38 micrograms/ml. A sural nerve biopsy showed a loss of large myelinated nerve fibers and a nonrandom clustered distribution of segmental demyelination and remyelination. The latter findings were accompanied by axonal shrinkage. Sixteen months after phenytoin was stopped, the patient's clinical and electrophysiological findings reflected improvement. These data indicate that long-term phenytoin administration can cause a reversible neuropathy characterized by axonal shrinkage and secondary demyelination.
23
Insufficient parahydroxylation as a cause of diphenylhydantoin toxicity
Henn Kutt, Michael Wolk, Rolf Scherman et al. · Neurology · 1964 · 179 citations
Effect of Diphenylhydantion on Peripheral Nerve
Frank Morrell, William E. Bradley, Mark Ptashne · Neurology · 1958 · 67 citations